Read by QxMD icon Read

ClinicoEconomics and Outcomes Research: CEOR

Lorie A Ellis, Elisabetta Malangone-Monaco, Helen Varker, Diana Stetsovsky, Maureen Kubacki, Raphael J DeHoratius, Shelly Kafka
Purpose: The objectives of this study were to evaluate and compare treatment patterns and infusion-related health care resource expenditures for rheumatoid arthritis (RA) patients initiating golimumab for intravenous use (GLM-IV) and infliximab (IFX) therapy and to assess cost implications from the commercial perspective. Methods: Adult RA patients with a new episode of GLM-IV or IFX treatment between Janu-ary 1, 2014 and March 31, 2016 were identified from MarketScan databases and evaluated for maintenance infusion intervals and related costs of treatment...
2019: ClinicoEconomics and Outcomes Research: CEOR
Anna Forsythe, Christina S Kwon, Timothy Bell, T Alexander Smith, Bhakti Arondekar
Background: AML is a rapidly progressing bone marrow cancer, with poor survival rates compared to other types of leukemia. IC and NIC as well as BSC treatment options are available; however, there is scant published literature on the impact of disease and treatment on the HRQoL in patients receiving NIC. Aim: This study determined the HRQoL among NIC AML patients. Materials and methods: Embase, Medline, Cochrane database, and conference abstracts were searched using the prespecified PICOS criteria from January 2000 to November 2017 for studies reporting HRQoL and patient preference utilities in NIC AML...
2019: ClinicoEconomics and Outcomes Research: CEOR
Stephané Roze, Jayne Smith-Palmer, Simona de Portu, Alexis Delbaere, Bonnie de Brouwer, Harold W de Valk
Aim: The aim of this study was to perform a cost-effectiveness analysis to establish the cost-effectiveness of sensor-augmented pump therapy (SAP) with automated insulin suspension vs continuous subcutaneous insulin infusion (CSII) alone in patients with type 1 diabetes in the Netherlands. Patients and methods: The analysis was performed using the IQVIA CORE Diabetes Model (CDM) in two different patient cohorts: one with suboptimal glycemic control at baseline (mean age 27 years, mean baseline HbA1c 8...
2019: ClinicoEconomics and Outcomes Research: CEOR
(no author information available yet)
[This corrects the article on p. 805 in vol. 10, PMID: 30532571.].
2019: ClinicoEconomics and Outcomes Research: CEOR
Kaoru Yamabe, Marco D DiBonaventura, Chris L Pashos
Purpose: Multiple sclerosis (MS) imposes a huge burden on patients. This study examined the relationship between MS and health-related and economic burden in Japan; secondarily, health status was compared across patients with MS in Japan, US, and five European Union (5EU) countries (France, Germany, Italy, Spain, and UK). Methods: A retrospective cross-sectional study was conducted using self-reported data from 2009 to 2014 Japan National Health and Wellness Survey (n=145,759)...
2019: ClinicoEconomics and Outcomes Research: CEOR
Jun Wu, Mary L Davis-Ajami, Zhiqiang K Lu
Purpose: Migraine prevalence increases in people with obesity, and obesity may contribute to migraine chronicity. Yet, few studies examine the effect of comorbid migraine on health care utilization and expenses in obese US adults. This study aimed to identify risk factors for migraine and compare the use of health care services and expenses between migraineurs and non-migraineurs in obese US adults. Subjects and methods: This 7-year retrospective study used longitudinal panel data from 2006 to 2013 from the Household Component of the Medical Expenditure Panel Survey to identify obese adults reporting migraines...
2019: ClinicoEconomics and Outcomes Research: CEOR
Jeffrey Trocio, Virginia M Rosen, Anu Gupta, Oluwaseyi Dina, Lien Vo, Patrick Hlavacek, Lisa Rosenblatt
Introduction: Direct oral anticoagulants (DOACs) have emerged as viable alternatives to traditional treatments such as vitamin K antagonists (VKAs) for venous thromboembolism (VTE). The objective of this review was to summarize evidence on the use of DOACs and VKAs to treat VTE in the US for patients transitioning from inpatient to post-discharge settings. Materials and methods: A systematic review of the VTE literature identified studies published in English (January 1, 2011-December 31, 2016) that reported inpatient and post-discharge treatments and discharge location...
2019: ClinicoEconomics and Outcomes Research: CEOR
Zheng-Yi Zhou, Wenxi Tang, Kathleen F Villa
Purpose: The study objective was to develop an economic model to assess projected costs of lost productivity associated with premature deaths due to veno-occlusive disease (VOD)/ sinusoidal obstruction syndrome (SOS) with multiorgan dysfunction (MOD) among patients in the US who underwent hematopoietic stem-cell transplant (HSCT) in 2013. Methods: Data sources included the US Census Bureau and Department of Health, epidemiologic research organizations, and medical research literature...
2019: ClinicoEconomics and Outcomes Research: CEOR
Kay Sadik, Jana Flener, Jeanine Gargiulo, Zachary Post, Steven Wurzelbacher, Andrew Hogan, Sarah Hollmann, Nicole Ferko
Background: Medicare's mandatory bundle for hip and knee arthroplasty necessitates provider accountability for quality and cost of care to 90 days, and wound closure may be a key area of consideration. The DERMABOND® PRINEO® Skin Closure System (22 cm) combines a topical skin adhesive with a self-adhering mesh without the need for dressing changes or suture or staple removal. This study estimated the budget impact of the Skin Closure System compared to other wound closure methods for hip and knee arthroplasty...
2019: ClinicoEconomics and Outcomes Research: CEOR
Jeroen P Jansen, Javaria Mona Khalid, Michael D Smyth, Haridarshan Patel
The number needed to treat (NNT) is considered an intuitive as well as popular effect measure. The aims of this review were to 1) explain why we cannot compare trial-specific NNT estimates for the competing treatments evaluated in different randomized controlled trials (RCTs) and 2) outline the principles of how relative treatment effects of different trials can be compared and results can be presented as NNT, without violating the principles of valid between-trial comparisons. Our premise is that ratio measures for relative treatment effects of response outcomes are less prone to effect modification than absolute difference measures of response outcomes...
2018: ClinicoEconomics and Outcomes Research: CEOR
Kathryn Fitch, Jocelyn Lau, Tyler Engel, Joseph J Medicis, John F Mohr, William S Weintraub
Purpose: The aim of this study was to quantify the potential cost savings to Medicare of shifting the site of treatment for worsening heart failure (HF) from inpatient to outpatient (OP) settings for a subset of worsening HF episodes among the Medicare fee-for-service (FFS) population. Materials and methods: A cross-sectional analysis of a random 5% sample of 2014 FFS Medicare beneficiaries was conducted. Incidence and cost of worsening HF episodes in both inpatient and OP settings were identified...
2018: ClinicoEconomics and Outcomes Research: CEOR
Naghmeh Foroutan, Jean-Eric Tarride, Feng Xie, Mitchell Levine
Introduction: Budget impact analysis (BIA) in health care, sometimes referred to as resource impact, is the financial change in the use of health resources associated with adding a new drug to a formulary or the adoption of a new health technology. Several national and transnational organizations worldwide have updated their BIA guidelines in the past 4 years. The aim of the present review was to provide a comprehensive list of the key recommendations of BIA guidelines from different countries that may be of interest for those who wish to build or to update BIA guidelines...
2018: ClinicoEconomics and Outcomes Research: CEOR
Cheryl P Ferrufino, Julie Munakata, Wenhui Wei, Clare Proudfoot, Andreas Kuznik, Susan H Boklage, Chieh-I Chen
Objective: To estimate the 5-year budget impact (BI) on a US health plan of introducing sarilumab - a human immunoglobulin G1 anti-IL-6 receptor α monoclonal antibody - as combination treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or monotherapy in patients with moderate-to-severe rheumatoid arthritis (RA). Methods: BI analysis was conducted from a commercial payer perspective. Treatment-eligible populations included adult patients with moderate-to-severe RA and inadequate response (IR) to csDMARDs or tumor necrosis factor (TNF)-α inhibitors-IR...
2018: ClinicoEconomics and Outcomes Research: CEOR
Dhvani Shah, Nancy A Risebrough, Johnna Perdrizet, Neeraj N Iyer, Cory Gamble, Tam Dang-Tan
Background: The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcomes Results (LEADER) clinical trial demonstrated that liraglutide added to standard-of-care (SoC) therapy for type 2 diabetes (T2D) with established cardiovascular disease (CVD) or elevated cardiovascular (CV) risk was associated with lower rates of death from CVD, nonfatal myocardial infarction (MI), or nonfatal stroke than SoC alone. Objective: The objective of this study was to assess the cost-effectiveness (CE) and budget impact of liraglutide vs SoC in T2D patients with established CVD or elevated CV risk, over a lifetime horizon from a US managed care perspective...
2018: ClinicoEconomics and Outcomes Research: CEOR
Elena Galve-Calvo, Eva González-Haba, Joana Gostkorzewicz, Irene Martínez, Alejandro Pérez-Mitru
Purpose: The aim of this study was to evaluate the cost-effectiveness of ribociclib compared to palbociclib, both in combination with letrozole, in the first-line treatment of postmenopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (ABC) from the perspective of the Spanish National Health System (NHS). Patients and methods: Disease progression was simulated with a partitioned survival model developed from the parameterization and extrapolation of survival curves of postmenopausal women with HR+/HER2- ABC from clinical trials with ribociclib or palbociclib, both in combination with letrozole...
2018: ClinicoEconomics and Outcomes Research: CEOR
Katherine Etter, Nadia Sutton, David Wei, Andrew Yoo
Objective: The objective of this study was to explore adhesion-related complications (ARCs) within 1 year after colectomy. Methods: Using Truven MarketScan® Commercial and Medicare databases, the first inpatient colectomies during 2009-2013 (index) were identified: left, right, partial, transverse, or total. One-year continuous enrollment was required pre and postindex. Only the first inpatient rehospitalization event was analyzed. ARC was defined as the subset of rehospitalizations with a diagnosis of ileus, small bowel obstruction, or postindex adhesiolysis...
2018: ClinicoEconomics and Outcomes Research: CEOR
Erin Johansson, Mercedes Nuñez, Axel Svedbom, Tatiana Dilla, Susanne Hartz
Background: Currently, several biologic agents are available for the treatment of moderate-to-severe plaque psoriasis, including newer agents with similar mechanisms of action and efficacy; therefore, there is a need to evaluate their efficiency in terms of cost effectiveness. Objective: This study evaluates the cost effectiveness of recently approved interleukin (IL)-17A antagonists, ixekizumab and secukinumab, for the treatment of moderate-to-severe plaque psoriasis from the perspective of the Spanish National Health System (NHS)...
2018: ClinicoEconomics and Outcomes Research: CEOR
Massimiliano Povero, Antonio Miceli, Lorenzo Pradelli, Matteo Ferrarini, Matteo Pinciroli, Mattia Glauber
Background: Meta-analyses of studies comparing transcatheter aortic valve implants (TAVIs) and sutureless aortic valve replacement (SU-AVR) show differing effectiveness and safety profiles. The approaches also differ in their surgical cost (including operating room and device). Objective: The objective of this study was to assess the incremental cost-utility of SU-AVR vs TAVIs for the treatment of intermediate- to high-risk patients in the US, Germany, France, Italy, UK, and Australia...
2018: ClinicoEconomics and Outcomes Research: CEOR
(no author information available yet)
[This corrects the article on p. 389 in vol. 10, PMID: 30087571.].
2018: ClinicoEconomics and Outcomes Research: CEOR
Daria J O'Reilly, Gord Blackhouse, Sheri Burns, James M Bowen, Natasha Burke, Jeff Mehltretter, Nancy M Waite, Sherilyn Kd Houle
Objective: The aim of this study was to evaluate the impact of pharmacist administration of influenza vaccine in Ontario on: 1) vaccination-associated costs related to the number of people vaccinated; 2) annual influenza-related outcomes and costs; and 3) change in productivity costs. Methods: Using available data for Ontario, the total number of vaccinations given by providers in the 2011/12 influenza season (pre) was compared to the 2013/14 influenza season (post)...
2018: ClinicoEconomics and Outcomes Research: CEOR
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"